CHINARES PHARMA (03320) subsidiary CHINARES PHARMA Business completes issuance of 1.4 billion yuan corporate bonds.
China Resources Pharmaceutical Group (03320) announced that its non-wholly-owned subsidiary, China Resources Pharmaceutical Commercial Group Co., Ltd. (China Resources Pharmaceutical Commercial), has successfully completed the public issuance of the second tranche of 2026 corporate bonds in China. The second tranche of 2026 corporate bonds, amounting to RMB 1.4 billion, has been issued with a maturity of 3 years and a coupon rate of 1.65%.
CHINARES PHARMA (03320) announced that its non-wholly owned subsidiary CHINARES PHARMA Commercial Group Limited (CHINARES PHARMA Commercial) has completed the issuance of the second tranche of 2026 corporate bonds in China. The second tranche of 2026 corporate bonds with a total amount of 1.4 billion yuan has been issued, with a term of 3 years and a coupon rate of 1.65%.
The net proceeds from the issuance of the second tranche of 2026 corporate bonds will be used for productive expenditures, including supplementing working capital, repaying interest-bearing debts, project investments, and other purposes in compliance with applicable laws and regulations.
Related Articles
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
J&T EXPRESS-W (01519) spent 23.4103 million Hong Kong dollars to repurchase 2.284 million shares on April 28th.
UNITED LAB (03933): TUL321 Capsules receive approval for new drug clinical trials by the US FDA.
LEGENDHOLDING (03396) will distribute a final dividend of 0.1 yuan per share on August 28th.
